Synthetic triterpenoid CDDO derivatives modulate cytoprotective or immunological properties in astrocytes, neurons, and microglia.
2-Cyano-3,12-dioxoolean-1, 9-dien-28-oic acid (CDDO) is a semisynthetic triterpenoid. CDDO derivatives with an amide, butyl ester (BE), imidazolide (IM), or trifluoroethyl amide (TFEA) group at position C-28 of CDDO were evaluated in glial and neuronal cells, in vitro. Changes in intracellular NADPH:quinone oxidoreductase (NQO1) levels, protection against oxidative toxicity, endotoxin-induced free-radical production, and the median lethal concentration (LC50) were assessed. All four CDDO derivatives at nanomolar concentrations increased NQO1 levels in astrocytes and moderately in neurons, but not in microglial cells. Pretreatment with 100 nM of CDDO-amide, CDDO-TFEA, or CDDO-IM protected astrocytes from hydrogen peroxide toxicity. Only CDDO-amide protected neuronal cells. Pretreatment of microglial cells with CDDO derivatives at nanomolar concentrations attenuated endotoxin-induced nitric oxide protection. The effectiveness for NQO1 induction, protection against oxidative toxicity, and attenuation of nitric oxide production, as well as cell viability at higher concentrations, varied among the derivatives with different functional groups at C-28. CDDO-amide had comparable or even a greater effectiveness at altering cytoprotective and immunomodulatory properties while having higher LC50 values for each neural cell type examined. These results indicate that derivatives of CDDO modulate important pathways relevant to many neurological diseases that involve both chronic inflammation and free-radical damage with variable effects based on the functional group at C-28 and cell type.
Graber
David J
DJ
Department of Pathology, Dartmouth Medical School, Lebanon, NH 03756, USA.
Park
Paul J
PJ
Hickey
William F
WF
Harris
Brent T
BT
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology; D001253:Astrocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D019610:Cytoprotection / Q000187:drug effects; D017628:Microglia / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D009828:Oleanolic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
C116817:2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid; D000975:Antioxidants; D018696:Neuroprotective Agents; D009828:Oleanolic Acid
J Neurosci. 1986 Aug;6(8):2163-78
3018187
Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620-4
2154753
PLoS One. 2009 Jun 01;4(6):e5757
19484125
J Neuroinflammation. 2008 May 12;5:14
18474101
J Biol Chem. 2000 May 26;275(21):16023-9
10821856
Mol Endocrinol. 2000 Oct;14(10):1550-6
11043571
Bioorg Med Chem Lett. 2005 May 2;15(9):2215-9
15837296
Biochem Biophys Res Commun. 2009 Mar 13;380(3):449-53
19174151
J Neurooncol. 1994;22(3):191-200
7760095
Anal Biochem. 1988 Mar;169(2):328-36
3382006
Cancer Res. 1998 Feb 15;58(4):717-23
9485026
Cancer Res. 2003 Sep 1;63(17):5551-8
14500394
Front Biosci. 2004 Jan 01;9:763-76
14766406
Free Radic Biol Med. 2010 Jul 15;49(2):147-58
20338236
Mol Pharmacol. 2001 May;59(5):1094-9
11306692
J Med Chem. 2000 Nov 2;43(22):4233-46
11063620
Cell. 2010 Mar 19;140(6):798-804
20303871
Methods Enzymol. 2004;382:243-58
15047106
Mol Cancer Ther. 2006 Dec;5(12):3232-9
17148759
J Immunoassay Immunochem. 2006;27(1):31-44
16450867
Cell. 2010 Mar 19;140(6):805-20
20303872
J Neurochem. 2009 Apr;109(2):502-12
19200343
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11908-13
12193649
Eur J Pharmacol. 2005 Oct 3;521(1-3):9-20
16171798
Antioxid Redox Signal. 2003 Jun;5(3):319-35
12880486
Free Radic Biol Med. 2007 Sep 1;43(5):809-17
17664144
Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4584-9
15767573
Alcohol. 1999 Feb;17(2):163-8
10064385
J Med Chem. 2000 May 4;43(9):1866-77
10794703
Neurochem Res. 1997 Oct;22(10):1187-92
9342721
Cancer Res. 1999 Jan 15;59(2):336-41
9927043
Neuroscience. 2007 May 25;146(3):1013-9
17418957
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
6606682
Cancer Res. 2004 Nov 1;64(21):7927-35
15520199
J Neurosci. 2008 Dec 10;28(50):13574-81
19074031
Bioorg Med Chem Lett. 1998 Oct 6;8(19):2711-4
9873608
Mol Cancer Ther. 2007 Jan;6(1):154-62
17237276
J Neurosci. 1998 Sep 15;18(18):7361-71
9736656
J Neuroimmunol. 1990 May;27(2-3):229-37
2110186
Glia. 2007 Oct;55(13):1362-73
17654704
J Neurochem. 2001 Mar;76(6):1670-8
11259485
Curr Pharm Des. 2004;10(8):879-91
15032691
J Immunol. 2004 Sep 15;173(6):3916-24
15356140
Mol Cell Biol. 2006 Jan;26(1):221-9
16354693
Cancer Res. 2005 Jun 1;65(11):4789-98
15930299
Neurosci Lett. 2006 Sep 25;405(3):168-71
16857315
Biochem Pharmacol. 2010 Feb 1;79(3):350-60
19782051
Biochem Biophys Res Commun. 2006 Dec 29;351(4):883-9
17097057
J Neurosci. 2003 Apr 15;23(8):3394-406
12716947
Biochem Pharmacol. 2008 Oct 15;76(8):967-73
18755157
Free Radic Biol Med. 2009 Aug 1;47(3):300-6
19410644
J Clin Biochem Nutr. 2009 Jan;44(1):79-84
19177192
Free Radic Biol Med. 2001 Feb 15;30(4):389-92
11182294
Inflamm Res. 2010 Jun;59(6):443-50
19924513
J Neuroimmunol. 1995 Dec 31;63(2):163-74
8550814
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4288-93
16857804
J Neurosci. 2004 Feb 4;24(5):1101-12
14762128
Glia. 2005 Oct;52(1):78-84
15920727
J Neurochem. 2002 Jun;81(6):1233-41
12068071
Cancer Res. 2008 Apr 15;68(8):2920-6
18413761
J Immunol. 2008 Jul 1;181(1):680-9
18566435
Cancer Res. 2007 Mar 15;67(6):2414-9
17363558
Dev Dyn. 1992 Jul;194(3):209-21
1467557